NovoCure (NASDAQ:NVCR – Get Free Report) and Nano-X Imaging (NASDAQ:NNOX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.
Institutional & Insider Ownership
84.6% of NovoCure shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 6.6% of NovoCure shares are owned by insiders. Comparatively, 7.7% of Nano-X Imaging shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
NovoCure has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Nano-X Imaging has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Profitability
This table compares NovoCure and Nano-X Imaging’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NovoCure | -16.78% | -35.81% | -15.14% |
| Nano-X Imaging | -926.05% | -116.93% | -100.67% |
Valuation & Earnings
This table compares NovoCure and Nano-X Imaging”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NovoCure | $655.35 million | 1.91 | -$136.23 million | ($1.06) | -10.10 |
| Nano-X Imaging | $15.63 million | 1.16 | -$75.02 million | ($2.14) | -0.11 |
Nano-X Imaging has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and target prices for NovoCure and Nano-X Imaging, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NovoCure | 1 | 4 | 3 | 0 | 2.25 |
| Nano-X Imaging | 1 | 2 | 2 | 0 | 2.20 |
NovoCure currently has a consensus price target of $22.33, indicating a potential upside of 108.53%. Nano-X Imaging has a consensus price target of $4.33, indicating a potential upside of 1,784.06%. Given Nano-X Imaging’s higher probable upside, analysts plainly believe Nano-X Imaging is more favorable than NovoCure.
Summary
NovoCure beats Nano-X Imaging on 9 of the 14 factors compared between the two stocks.
About NovoCure
NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a cancer treatment that uses wearable devices to deliver low-intensity electric fields intended to disrupt cancer cell division. Its products include Optune Gio and Optune Lua, which are used to treat certain cancers. The company is headquartered in Baar, Switzerland, and serves patients in markets across North America, Europe and Asia. NovoCure was founded in 2000 by Yoram Palti, a medical researcher who developed the TTFields approach.
About Nano-X Imaging
Nano-X Imaging Ltd. is an Israeli medical technology company developing digital X-ray imaging systems and related services. Its Nanox.ARC system is designed to produce medical images using the company’s digital X-ray technology, with the goal of expanding access to diagnostic imaging. The company’s broader offering includes Nanox.CLOUD, a cloud-based platform intended to connect imaging systems with image-management and diagnostic services, and Nanox.AI, which develops artificial-intelligence tools for analyzing medical images.
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
